Expanding the potential for epigenetic targeting therapies in Prostate cancer: Histone deacetylase inhibition sensitizes prostate cancer cells to radiotherapy.

Original language	English
Publication status	Published - 28 Nov 2017
Event	1st European Alliance for Personalised Medicine Congress 2017 - Belfast, United Kingdom Duration: 25 Nov 2017 → 30 Nov 2017

Conference

Conference	1st European Alliance for Personalised Medicine Congress 2017
Country/Territory	United Kingdom
City	Belfast
Period	25/11/2017 → 30/11/2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

1. 
   SDG 3 Good Health and Well-being

Student theses

• Integration of class 1 HDAC inhibitors into current treatments for prostate cancer

  Manley, J. (Author), LaBonte Wilson, M. (Supervisor) & Waugh, D. (Supervisor), Dec 2020

  Student thesis: Doctoral Thesis › Doctor of Philosophy

  File

Cite this

• APA
• Author
• BIBTEX
• Harvard
• Standard
• RIS
• Vancouver

Manley, J., Maxwell, P., & LaBonte Wilson, M. (2017). Expanding the potential for epigenetic targeting therapies in Prostate cancer: Histone deacetylase inhibition sensitizes prostate cancer cells to radiotherapy.. Abstract from 1st European Alliance for Personalised Medicine Congress 2017, Belfast, United Kingdom.

Manley, Judith ; Maxwell, Pamela ; LaBonte Wilson, Melissa. / Expanding the potential for epigenetic targeting therapies in Prostate cancer: Histone deacetylase inhibition sensitizes prostate cancer cells to radiotherapy. Abstract from 1st European Alliance for Personalised Medicine Congress 2017, Belfast, United Kingdom.

@conference{6ab3307613e949b59d7822b602a1a928,

title = "Expanding the potential for epigenetic targeting therapies in Prostate cancer: Histone deacetylase inhibition sensitizes prostate cancer cells to radiotherapy.",

author = "Judith Manley and Pamela Maxwell and \{LaBonte Wilson\}, Melissa",

year = "2017",

month = nov,

day = "28",

language = "English",

note = "1st European Alliance for Personalised Medicine Congress 2017 ; Conference date: 25-11-2017 Through 30-11-2017",

}

Manley, J, Maxwell, P & LaBonte Wilson, M 2017, 'Expanding the potential for epigenetic targeting therapies in Prostate cancer: Histone deacetylase inhibition sensitizes prostate cancer cells to radiotherapy.', 1st European Alliance for Personalised Medicine Congress 2017, Belfast, United Kingdom, 25/11/2017 - 30/11/2017.

Expanding the potential for epigenetic targeting therapies in Prostate cancer: Histone deacetylase inhibition sensitizes prostate cancer cells to radiotherapy. / Manley, Judith; Maxwell, Pamela; LaBonte Wilson, Melissa.
2017. Abstract from 1st European Alliance for Personalised Medicine Congress 2017, Belfast, United Kingdom.

Research output: Contribution to conference › Abstract › peer-review

TY - CONF

T1 - Expanding the potential for epigenetic targeting therapies in Prostate cancer: Histone deacetylase inhibition sensitizes prostate cancer cells to radiotherapy.

AU - Manley, Judith

AU - Maxwell, Pamela

AU - LaBonte Wilson, Melissa

PY - 2017/11/28

Y1 - 2017/11/28

M3 - Abstract

T2 - 1st European Alliance for Personalised Medicine Congress 2017

Y2 - 25 November 2017 through 30 November 2017

ER -

Manley J, Maxwell P, LaBonte Wilson M. Expanding the potential for epigenetic targeting therapies in Prostate cancer: Histone deacetylase inhibition sensitizes prostate cancer cells to radiotherapy.. 2017. Abstract from 1st European Alliance for Personalised Medicine Congress 2017, Belfast, United Kingdom.